ISCHEMIA-EXTEND studies: Rationale and design

• Published in: The American heart journal Vol. 254; pp. 228 - 233
• Main Authors: Anthopolos, Rebecca, Maron, David J., Bangalore, Sripal, Reynolds, Harmony R., Xu, Yifan, O'Brien, Sean M., Troxel, Andrea B., Mavromichalis, Stavroula, Chang, Michelle, Contreras, Aira, Hochman, Judith S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2022; Elsevier Limited
• Subjects: Angina pectoris; Angiography; Bayes Theorem; Bayesian analysis; Cardiac catheterization; Cardiovascular diseases; Clinical trials; Coronary Disease; Death; Exercise Test; Health policy; Health risks; Health services; Heart attacks; Heart diseases; Heart failure; Humans; Intubation; Ischemia; Kidney diseases; Medical imaging; Medical records; Mortality; Myocardial infarction; Myocardial Infarction - therapy; Patients; Quality of life; Renal Insufficiency, Chronic - therapy; Risk management; Strategy; Survival; United Kingdom > UK; Poland; United States > US
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2022.09.009

The ISCHEMIA and the ISCHEMIA-CKD trials found no statistical difference in the primary clinical endpoint between initial invasive management and initial conservative management of patients with chronic coronary disease and moderate to severe ischemia on stress testing without or with advanced chronic kidney disease (CKD). In ISCHEMIA, there was numerically lower cardiovascular mortality but higher non-cardiovascular mortality with no significant difference in all-cause death with an initial invasive strategy when compared with a conservative strategy. However, an invasive strategy increased peri-procedural myocardial infarction (MI) but decreased spontaneous MI with continued separation of curves over time, which potentially may lead to reduced risk of cardiovascular and all-cause mortality. Thus, the long-term effect of invasive management strategy on mortality remains unclear. In ISCHEMIA-CKD, the treatment and cause-specific mortality rates were similar during follow-up. Funded by the National Heart, Lung, and Blood Institute, the ISCHEMIA-EXTEND observational study is the long-term follow-up of surviving participants (projected median of 10 years) with chronic coronary disease from the ISCHEMIA trial. In the ISCHEMIA trial, 5,179 participants with moderate or severe stress-induced ischemia were randomized to initial invasive management with angiography, revascularization when feasible, and guideline-directed medical therapy (GDMT), or initial conservative management with GDMT alone and angiography reserved for failure of medical therapy. ISCHEMIA-CKD EXTEND is the long-term follow-up of surviving participants (projected median of 9 years) from the ISCHEMIA-CKD trial, a companion trial that included 777 patients with advanced CKD. Ascertainment of death will be conducted via direct participant contact, medical record review, and/or vital status registry search. The overarching objective of long-term follow-up is to assess whether there are between-group differences in long-term all-cause, cardiovascular, and non-cardiovascular mortality, and increase precision around the treatment effect estimates for risk of all-cause, cardiovascular, and non-cardiovascular mortality. We will conduct Bayesian survival modeling to take advantage of rich inferences using the posterior distribution of the treatment effect. The long-term effect of an initial invasive versus conservative strategy on all-cause, cardiovascular, and non-cardiovascular mortality will be assessed. The findings of ISCHEMIA-EXTEND and ISCHEMIA-CKD EXTEND will inform patients, practitioners, practice guidelines, and health policy.